GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Class-action lawsuits are underway against Hims & Hers Health Inc., representing investors who bought or acquired company securities between April 29, 2025, and June 23, 2025. The lawsuit alleges that ...

Shares of Hims & Hers (HIMS) are down 92c, or 2%, to $45.09 in pre-market trading after GoodRx (GDRX) announced that all strengths of Ozempic and ...

Health Hims & Hers Will Sell Wegovy-Like Weight Loss Drugs for $199 The telehealth company's stock surged after the announcement Bruce Gil, Quartz Published May 20, 2024 | Comments (13) 𝕏 ...

Novo Nordisk cut ties with Hims & Hers over semaglutide concerns Company alleges illegal sales of unapproved Wegovy alternatives FDA limits compounding of GLP-1 drugs to patient-specific cases ...

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a new, affordable price. The company, via this offer, aims to make proven ...

On Tuesday, Hims & Hers announced a long-term collaboration with Denmark-based Novo Nordisk A/S (NVO), which makes Wegovy and diabetes-treatment Ozempic, which are both approved by the FDA.

SAN FRANCISCO, May 22, 2025--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven ...